Vogt-Koyanagi-Harada Disease

  title={Vogt-Koyanagi-Harada Disease},
  author={Emmett T. Cunningham and Sivakumar R. Rathinam and İlknur Tuğal-Tutkun and Cristina Muccioli and Manfred Zierhut},
  journal={Ocular Immunology and Inflammation},
  pages={249 - 252}
Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA, Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA, The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, CA, USA, Aravind Eye Hospital, Madurai, Tamil Nadu, India, Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, Department of Ophthalmology, Universidade Federal de São Paulo, São Paulo, Brazil, and… 
17 Citations
Subretinal Fibrosis in Uveitis
This research presents a novel and scalable approach to single-cell ophthalmology that allows for real-time, 3D image analysis of the retina and shows clear improvements in the ability of the eye to communicate with the brain.
Unilateral Vogt-Koyanagi-Harada Disease: A Clinical Case Report
The clinical and angiographic features were typical of Vogt-Koyanagi-Harada (VKH) disease, and ophthalmologists should be aware to recognize this rare clinical variant of the disease.
Treatment of Vogt-Koyanagi-Harada Disease
The combined therapy of immunosuppressive drugs with steroids was effective in improving visual impairment in a 29-year-old man referred with a two-week history of pain, redness, photophobia, and blurring of vision of the right eye.
Vogt-Koyanagi-Harada disease in Spain
VKH in Spain mostly affects women and presents as incomplete acute stage disease and visual prognosis is good, with cataract and glaucoma are the two most frequent complications.
Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment.
Retrospective case series of recurrent VKH uveitis treated with intravenous RTX showed that RTX was effective in VHK disease poorly controlled by traditional immunosuppressive treatment.
Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study
There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies, after a routine ophthalmological visit, and despite treatment, most patients with N IIPPU experienced a decline in ocular function and ocular complications.
The Role of Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt–Koyanagi–Harada Disease
OCTA allows high-resolution imaging of inflammatory foci suggestive of choriocapillaris hypoperfusion in acute VKH disease non-invasively and may be very helpful in the follow-up of such patients.
Vogt-Koyanagi-Harada. Reporte de un Caso y Revisión Bibliográfica
Se presenta el caso de una paciente femenina, que acude por disminución de agudeza visual en ambos ojos de 2 semanas de evolución, asociado a cefalea y tinnitus. Durante la exploración oftalmológica
Ocular Manifestations of Systemic Autoimmune Diseases
An integrated approach with close collaboration among ophthalmologists, neurologists, internists and pathologists is required to ensure optimal patient care, preserving not only the vision but also the lives of the patients.
Diagnostic and Therapeutic Challenges.
A 72-year-old Filipino woman with a long-standing history of severe unilateral vision loss in the right eye is presented, diagnosed with breast cancer for which she underwent mastectomy and has had no recurrence.


Vogt-Koyanagi-Harada disease.
  • R. Read
  • Medicine
    Ophthalmology clinics of North America
  • 2002
Vogt-Koyanagi-Harada Disease: Clinical and Demographic Characteristics of Patients in a Specialized Eye Hospital in Turkey
The disease is incomplete and acute in half of the patients and has a quite good visual prognosis and seems to have increased during the last few years in Turkey.
Vogt-Koyanagi-Harada disease.
Experimental data continue to support an autoimmune etiology for VKH disease, directed most probably against an antigenic component of the melanocyte, possibly tyrosinase or a tyros inase-related protein.
Vogt-Koyanagi-Harada Disease in Thailand
Cataract and glaucoma represented the common ocular complications of VKH and were not associated with a specific treatment regimen but with an early withdrawal of systemic corticosteroids.
The spectrum of Vogt-Koyanagi-Harada disease in Turkey
It is concluded that the majority of patients with VKH in Turkey do not have the complete form of the disease and are likely to be late referrals.
Retinal pigment epithelium folds as a diagnostic finding of Vogt-Koyanagi-Harada disease
The detection of the folds of the RPE on OCT is a simple and effective method to help diagnose VKH disease at its acute stage which does not require pupil dilation.
Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease.
Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease
Submaximal doses of inflammation suppressive therapy are sufficient to suppress clinically apparent disease but not the underlying lesion process, which explains the propensity for sunset glow fundus in seemingly controlled disease.